Agios Pharmaceuticals Inc. Stock
We can see a decrease in the price for Agios Pharmaceuticals Inc.. Compared to yesterday it has lost -€0.600 (-2.460%).
With 16 Buy predictions and not the single Sell prediction the community is currently very high on Agios Pharmaceuticals Inc..
As a result the target price of 36 € shows a positive potential of 50.0% compared to the current price of 24.0 € for Agios Pharmaceuticals Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Agios Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | -2.460% | 0.000% | 1.695% | -16.667% | 3.448% | 15.385% | -39.394% |
| United Therapeutics | 1.490% | 13.960% | 17.057% | 66.631% | 9.853% | 124.164% | 250.299% |
| Iovance Biotherapeutics Inc. | -1.520% | -21.720% | 59.719% | 6.635% | 46.016% | -42.790% | -88.067% |
| Ligand Pharmaceuticals | -6.250% | 1.667% | 16.561% | 69.444% | 10.241% | 191.773% | 33.091% |
Comments
Agios Pharmaceuticals (AGIO) had its price target raised by Citigroup Inc. from $38.00 to $46.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at HC Wainwright from $62.00 to $65.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $40.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
News
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
On February 17, 2026, Commodore Capital disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold all 2,338,287 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
On February 17, 2026, Rock Springs Capital Management LP disclosed in an SEC filing that it sold 159,379 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth quarter, an estimated $5.59
Here's Why Shares in Agios Pharmaceuticals Popped Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME